Oclacitinib for Controlling Pruritus and Associated Skin Lesions in 16 Horses With Allergic Dermatitis Authors: Maturawan Tunhikorn, Photchanun Maneephan, Natcha Tovanakasame, Chalidaporn Kampang, Pusprapa Jandee, Panpanga Sangsuriya, Nuttawut Nuchprayoon Published: 2026 ABSTRACT ABSTRACTBackgroundOclacitinib is a Janus kinase inhibitor approved for the treatment of pruritus associated with allergic dermatitis in dogs and may be effective in horses.ObjectivesTo evaluate the efficacy of oclacitinib in reducing pruritus and skin lesions in horses with allergic dermatitis.AnimalsSixteen horses aged ≥ 18 months.Materials and MethodsHorses received oclacitinib at 0.25 mg/kg orally once daily for 21 days. Changes in haematological and biochemical parameters were measured on Day (D)0 and D21. The owners were instructed to evaluate the horses using the pruritus Visual Analog Scale (PVAS) on D0, D4, D7, D10, D14, D17 and D21. A veterinary surgeon evaluated skin lesions using a veterinarian lesion score (VLS) and veterinarian alopecia score (VAS) on D0, D7, D14 and D21.ResultsFrom baseline to D21, the median (range) PVAS changed from 5 (4–8) to 2.5 (2–4.5), VLS from 19 (2–42) to 10 (1–38) and VAS from 2 (2, 3) to 2 (1, 2). Of all 16 horses, improvements in PVAS, VLS and VAS were observed in 15, 12 and 8 horses, respectively. Blood profiles revealed significantly increased aspartate aminotransferase, gamma‐glutamyl transferase and creatinine levels. White blood cell count, lymphocyte count and blood urea nitrogen significantly decreased. Creatine kinase levels showed individual variability.Conclusions and Clinical RelevanceOclacitinib effectively reduced pruritus and improved skin lesions in horses with allergic dermatitis. However, caution is advised when administering the drug to horses with renal, hepatic or muscular disorders. Introduction In horses, allergic dermatitis results from type I and type IV hypersensitivity reactions caused by allergens, most commonly insect bite hypersensitivity (IBH) [1], followed by adverse food reactions, dust exposure and others [2]. Pruritus typically manifests with signs such as scratching, rubbing and self‐trauma, resulting in wounds and secondary infection [1]. Associated skin lesions may include wheals (urticaria), excoriations, hypotrichosis, papules, crusts, scales, lichenification, erythema and hyperpigmentation [3]. Treatment options for pruritus include topical and systemic medications such as glucocorticoids, antihistamines and fatty acid supplementation, although evidence‐based studies regarding their efficacy remain limited [4]. Oclacitinib is a Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway inhibitor that primarily inhibits JAK1‐dependent cytokines involved in allergy, inflammation (interleukin [IL]‐2, IL‐4, IL‐6 and IL‐13) and pruritus (IL‐31) [5]. In humans, IL‐31 binds to receptors on peripheral nerve endings, stimulates brain‐derived natriuretic peptide production in skin cells and promotes pruritus [6]. Recently, IL‐31 has been found to mediate pruritus in horses [7]. Meanwhile, oclacitinib has been approved for the treatment of allergic pruritus and atopic dermatitis in dogs aged ≥ 12 months [8, 9]. A previous study administering oclacitinib orally to horses at a dose of 0.25 mg/kg once daily for 28 days demonstrated significant reduction in pruritic signs by Day 5 of treatment [10]. Pruritus affects the quality‐of‐life (QoL), performance and economic value of the affected horses, yet the studies on the efficacy and safety of oclacitinib in horses remain limited. Therefore, this pilot study aimed to evaluate the safety and efficacy of oclacitinib in reducing pruritus and skin lesions in horses with allergic dermatitis. Materials and Methods Animals This study was approved as per the animal care protocol of MUVS‐IACUC (MUVS‐2020‐11‐54), and the owners provided signed consent. Sixteen horses with allergic pruritus were enrolled aged ≥ 18 months and weighing > 200 kg. Allergic dermatitis was diagnosed by ruling out ectoparasitic infestations, bacterial and fungal infections and other pruritic skin diseases. Gestating and lactating mares were excluded from the study. Antihistamines, glucocorticoids and other topical antipruritic drugs were withheld for ≥ 3 weeks before study initiation. No dietary or husbandry management changes were permitted during the study period. A total of 16 horses (Overall Group) were included in this study, which were further classified into the Stable Group (n = 11) and Paddock Group (n = 5). The Stable Group horses were kept primarily in the stable and led out into the paddock for a few hours per day, while the Paddock Group horses lived out in the paddock throughout the day. Treatment Oclacitinib (Apoquel [Zoetis], 16 mg/tablet) was administered orally at a dose of 0.25 mg/kg once daily for 21 days at the same time each day. Horses were weighed at baseline (Day [D]0) to determine the appropriate drug dosage. Owners were allowed to administer the drug with or without food. The satisfaction score with oclacitinib treatment was rated by the owners on D21 using a four‐point scale (0 = poor, 1 = fair, 2 = good, 3 = excellent). Evaluation of Clinical Efficacy Three scoring systems were used to assess the severity of pruritus and clinical lesions. First, the pruritus Visual Analog Scale (PVAS), adapted from Cosgrove et al. [11] (Figure S1), was scored by the same owner for each horse at baseline (D0) and after drug administration (D4, D7, D10, D14, D17 and D21). Second, the veterinarian lesion score (VLS) was used to assess skin lesion severity across 13 lesion sites, as described by Olsen et al. [12] and Miller et al. [13] (Figure S2). Lastly, the veterinarian alopecia score (VAS) based on Miller et al. [13] was used to evaluate the severity of hair loss (Figure S2). The VLS and VAS were scored on D0, D7, D14 and D21 by the same veterinary surgeons. Adverse Effects and Safety Assessment Horses were monitored daily by owners and weekly by veterinary surgeons for adverse events, such as weight loss > 10% of baseline body weight, anorexia, dullness and diarrhoea. Treatment withdrawal was considered if severe adverse effects occurred. Changes in haematological and blood chemistry profiles were evaluated after the collection of jugular vein blood samples at baseline (D0) and after oclacitinib administration (D21). The following parameters were evaluated as follows: complete blood count (CBC), aspartate aminotransferase (AST), gamma‐glutamyl transferase (GGT), creatine kinase (CK), blood urea nitrogen (BUN) and creatinine (CREA). Statistical Analysis Data were analysed using spss statistics v30.0 (IBM). Normality was tested using the Shapiro–Wilk test. Statistical significance was set at p < 0.05. PVAS, VLS and VAS scores were compared across study time points within groups using the Friedman test. The same parameters were further compared between Stable and Paddock Group horses during each study time point using the median test. Changes in blood parameters were analysed using the Wilcoxon signed‐rank test. Results Animals and Treatment Table 1 summarises the breed, sex, age, body weight, husbandry and duration of clinical signs for each horse. Enrolled breeds included Thai pony (n = 8), Argentina polo pony (n = 4), Arabian × Thai pony (n = 1), Arabian × Burmese (n = 1), Dutch warmblood (n = 1) and American paint horse (n = 1). Horses had a median age of 16 years (range 5–23 years), body weight of 334 kg (range 214–445 kg) and duration of clinical signs of 4 years (range 1–10 years). TABLE 1Signalment and outcomes of pruritus Visual Analog Scale (PVAS), Veterinarian lesion score (VLS) and Veterinarian alopecia score (VAS) before (Day [D]0)and after (D21) oclacitinib treatment in 16 horses with allergic dermatitis.FarmAge (years)SexBreedColourHusbandryType of workWeight (kg)Duration of sign (years)PVAS D0PVAS D21VLS D0VLS D21VAS D0VAS D21A17GeldingDutch warmbloodBayStableWorking37287320832A17MareAmerican paint horsePiebaldStableWorking445104.54.5203222B8GeldingThai ponyBayStableResting350352422332B15GeldingThai ponyChestnutStableResting293962301422C23MareThai ponyPiebaldStableWorking2145432121C21GeldingThai ponyBayStableWorking2985437422C15GeldingThai ponyBayPaddockResting21416419632D18MareThai ponyChestnutStableResting30354.5419922D15MareThai ponyChestnutStableResting308554121122E15MareArgentina polo ponyBayPaddockResting414342283121E20MareArgentina polo ponyDunPaddockResting356152183822E18MareArgentina polo ponyChestnutPaddockResting390152202322E10MareArgentina polo ponyChestnutPaddockResting420372413322F5MareArabian x BurmeseChestnutStableWorking41114213821G10MareThai ponyChestnutStableWorking3182425321G17GeldingArabian x Thai ponyDunStableWorking2565848721 Signalment and outcomes of pruritus Visual Analog Scale (PVAS), Veterinarian lesion score (VLS) and Veterinarian alopecia score (VAS) before (Day [D]0)and after (D21) oclacitinib treatment in 16 horses with allergic dermatitis. Haematological and biochemical profiles were analysed before prescribing oclacitinib (Table S1). Although some horses had high CK (horses 4, 5, 6, 11, 12 and 14), low platelet counts (horses 2, 5, 6, 8, 10, 11, 13 and 14), high haematocrit (Horse 5) and high lymphocyte and monocyte counts (Horse 8), they were included in this study as these abnormalities could be attributed to factors such as age and workload. Oclacitinib was administered at a mean dose of 0.25 mg/kg (range 0.25–0.27 mg/kg) orally once daily for 21 days. Evaluation of Clinical Efficacy On D21, PVAS values decreased in 15 of 16 horses, indicating reduced pruritus. VLS decreased in 12 horses. VAS improved in eight horses, indicating hair recovery (Table 1). Figure 1 illustrates the median and range of PVAS values. A reduction in PVAS was observed from D0 to D21 across all groups. The clinical signs of pruritus began to improve significantly in the Overall Group by D4 (p = 0.033). A significant reduction in PVAS was observed on D7 in the Stable Group (p = 0.002) and D10 in the Paddock Group (p = 0.013). PVAS continued to decrease gradually in the Overall and Paddock Groups until D21. However, the Stable Group showed a slight rebound during D7. Pruritus Visual Analog Scale (PVAS) scores during treatment with oclacitinib in horses with allergic dermatitis. Statistical differences within each group are indicated by a, b and c (p < 0.05). Figure 2 illustrates the median and range of VLS values, wherein higher values indicate more severe skin lesions. VLS on D21 was significantly decreased compared with that on D0 in the Overall Group (p = 0.047) and Stable Group (p = 0.008). However, VLS significantly increased in the Paddock Group from D0 to D14 (p = 0.027). Veterinarian lesion score (VLS) during treatment with oclacitinib in horses with allergic dermatitis. Statistical differences within each group are indicated by a, b and c (p < 0.05). Figure 3 illustrates the median and range of VAS, wherein higher values indicate worsening alopecia. VAS on D21 was significantly decreased compared with that on D0 in the Overall Group (p = 0.028) and Stable Group (p = 0.048). However, no significant change in VAS was observed in the Paddock Group (p > 0.05). Veterinarian alopecia score (VAS) during treatment with oclacitinib in horses with allergic dermatitis. Statistical differences within each group are indicated by a, b and c (p < 0.05). Comparing the Stable versus Paddock Groups, no significant changes were observed in PVAS, VLS and VAS at any time point (p > 0.05). In this study, the most prevalent skin lesions were crusts, papules, blood exudates and wheals. These lesions were frequently detected on the neck (location 4), forelimb groins (location 11), chest (location 5) and ventral abdomen (location 8), respectively (Figure S2). Among seven farm owners (Table 1), owner satisfaction with oclacitinib treatment was rated as either excellent (n = 1), good (n = 5) or fair (n = 1). Adverse Effects and Safety Assessment No clinical adverse events that could likely be related to drug administration were detected during the study period. Before oclacitinib administration, the median and range of haematological and biochemical parameters were within the normal reference ranges (Table 2). After oclacitinib administration, significant reductions in white blood cell count (p = 0.023), lymphocyte count (p = 0.039) and BUN concentrations (p = 0.037) were observed. Conversely, significant elevations in AST (p = 0.009), GGT (p = 0.003) and CREA concentrations (p = 0.013) were noted. Nevertheless, all median values remained within the normal reference ranges. The individual values are presented in Tables S1 and S2. Changes in CK concentrations exhibited individual variability. However, Horse 11 showed increased AST and decreased BUN concentrations that exceeded reference ranges after treatment. TABLE 2Median and range of haematological and biochemical parameters before (Day [D]0) and after (D21) treatment with oclacitinib.ParametersReferencesD0D21 p Red blood cell (106/μL)6.0–10.46.82 (5.03–7.81)6.80 (4.92–8.62)0.326Haemoglobin (g/dL)10.1–16.111.6 (8.5–13.6)11.5 (8.3–14.3)0.334Haematocrit (%)27.0–45.034.8 (25.6–47.8)33.9 (24.8–41.4)0.959White blood cell (103/μL)5.6–12.18.97 (7.00–10.69)8.28 (7.37–11.08)0.023*Neutrophils (103/μL)2.91–8.475.87 (4.34–7.89)5.73 (5.17–7.41)0.796Lymphocytes (103/μL)1.18–5.082.88 (1.64–6.61)2.00 (0.11–3.55)0.039*Eosinophils (103/μL)0.0–0.850.05 (0.00–0.73)0.10 (0.00–0.45)0.408Monocytes (103/μL)0.0–0.730.19 (0.09–1.04)0.25 (0.07–0.40)0.605Platelet count (103/μL)117.0–256.0113.0 (45.0–212.0)129.0 (99.0–217.0)0.088Plasma protein (g/dL)6.0–8.57.0 (4.2–8.0)7.0 (5.0–8.0)0.472AST (U/L)160.0–412.0282.5 (212.0–412.0)299.5 (225.0–440.0)0.009*GGT (U/L)6.0–32.014.8 (7.8–23.4)18.6 (6.7–35.7)0.003*BUN (mg/dL)11.0–27.014.5 (7.0–26.0)12.0 (4.0–23.0)0.037*CREA (mg/dL)0.40–2.201.49 (1.25–2.12)1.59 (1.26–2.17)0.013*CK (U/L)60.0–330.0278.0 (118.0–703.0)287.0 (133.0–592.0)0.756 Note: Significance: *p < 0.05.Abbreviations: AST, aspartate aminotransferase; BUN, blood urea nitrogen; CK, creatinine kinase; CREA, creatinine; GGT, gamma‐glutamyl transferase. Median and range of haematological and biochemical parameters before (Day [D]0) and after (D21) treatment with oclacitinib. Note: Significance: *p < 0.05. Abbreviations: AST, aspartate aminotransferase; BUN, blood urea nitrogen; CK, creatinine kinase; CREA, creatinine; GGT, gamma‐glutamyl transferase. Discussion Oclacitinib administration at 0.25 mg/kg once daily for 21 days effectively controlled pruritus and led to an improvement in skin lesions. Physical examinations revealed no adverse effects, although minor changes in blood parameters were observed following the 21 day treatment period. As a JAK inhibitor, oclacitinib inhibits the release of proinflammatory (IL‐2 and IL‐6), proallergenic (IL‐4 and IL‐13) and pruritogenic (IL‐31) cytokines [5]. In particular, IL‐31 has been identified as a mediator of pruritus in horses, as pruritus was observed after the injection of recombinant equine IL‐31 [7]. In another study, IL‐31 was detected in the skin biopsy samples of IBH lesions, yet it was undetectable in healthy horses and those with clinical sign‐free IBH. Moreover, horses with IBH that were vaccinated against equine IL‐31 experienced alleviation of clinical scores [14]. In line with these findings, oclacitinib administration in our study alleviated pruritus in horses with allergic dermatitis, further supporting the critical role of IL‐31 in equine pruritus. Oclacitinib can successfully reduce pruritus associated with atopic dermatitis and allergic dermatitis in dogs, as well as nonflea, nonfood‐induced hypersensitivity dermatitis in cats [11, 15, 16]. In dogs, oclacitinib is administered at a dose of 0.4–0.6 mg/kg p.o. twice daily for 14 days, followed by once‐daily administration for long‐term treatment [9, 15]. In cats, off‐licence oclacitinib administration has been described in two studies at doses of 0.7–1.2 mg/kg p.o. twice daily for 28 days [17] and 1 mg/kg p.o. twice daily for 28 days [18]. Pharmacokinetic studies of oclacitinib in horses are scarce. Although high bioavailability has been reported in dogs (89%) and cats (87%) [19, 20], this remains unknown for horses. The mean maximum plasma drug concentration (C max) after oclacitinib administration was 324 mg/mL in dogs and 1631.6 mg/mL in cats [19, 20], while horses had C max values of 204 and 486 ng/mL at doses of 0.2 and 0.5 mg/kg, respectively [21, 22]. The time of maximum plasma concentration (T max) was approximately < 1 h in dogs and 35 min in cats. Meanwhile, horses had T max values of 3.7 and 1.7 h at doses of 0.2 and 0.5 mg/kg, respectively. Oclacitinib has a half‐life of 4.1 and 2.3 h in dogs and cats, respectively, while in horses, this ranges from 7.5 to 8 h across both oral and intravenous administration [19, 20, 21, 22]. This relatively longer half‐life in horses supports the hypothesis that once‐daily dosing can sufficiently maintain the plasma concentrations required to control pruritus in horses. Improvement in pruritic signs in the Overall Group was detected on D4. In line with this finding, a previous study initially detected a reduction in pruritus on D5 following oral oclacitinib administration at a dose of 0.25 mg/kg [10]. However, between D7 and D17 of our study, PVAS scores in the Stable Group rebounded and exceeded those of the Paddock Group. This is likely to have resulted from seasonal insect pressure. Horses 5–16 were treated during the rainy season (June to September), when high humidity and rainfall increase biting insect activity. Despite using fans and mosquito netting, the Stable Group was pastured for 3–6 h daily. Netting was only utilised from dusk to dawn, as it restricted the wind flow and led to heat accumulation during daylight hours. The efficacy of the oclacitinib may be overwhelmed by high insect density and prolonged exposure. For instance, Farm C is located near coastal and mountainous terrain and horses 5 and 6 (Stable Group) remained in the paddock longer here than horses at other farms (6–8 h per day). Consequently, horses 5 and 6 exhibited high PVAS scores (score 6) compared to the rest of the cohort. The VLS and VAS findings in the Overall Group indicated that the skin lesions required ≥ 21 days for improvement. A previous study investigating the length of hair regrowth in dogs after clipping found that hair regrowth took 14.5 weeks during summer [23]. As domestic horses have an average tail hair growth of 0.57 mm/day, the expected hair growth on D21 is estimated to be 12 mm under healthy skin conditions [24]. However, the alopecic lesions did not demonstrate significant improvement during our study period of 21 days. A longer study period is likely to be required to appropriately observe the progression of hair growth. In the Paddock Group, VLS significantly increased by D14, yet VAS did not significantly change during the study period. Alongside the decrease in PVAS, these data suggest that oclacitinib helped improve pruritus. However, the skin lesions might not improve if environmental control is lacking, especially because these horses staying outside in the paddock were heavily exposed to insects. By contrast, horses that were housed in the stable were protected by insect netting and fans inside each stall. Horses in the Stable Group also tended to receive more grooming, showering and insect repellent spraying than the Paddock Group. Therefore, environmental control is crucial for improving skin lesions in horses with allergic dermatitis. Regarding safety, biochemical findings revealed elevations in AST, GGT and CREA, as well as reduced BUN, although all biochemical profiles remained within normal range and were not life‐threatening. Meanwhile, a case report of oclacitinib overdose toxicity in a dog monitored the biochemical changes for 84 h after drug ingestion. An increase in CREA was detected within 24 h, yet the value was within the reference range. BUN and GGT levels also were normal, despite ingesting a presumed dose of 27.3 mg/kg, which is > 100‐fold greater than the normal dose of 0.25 mg/kg [25]. Another study involving 20 cats reported that oclacitinib at a dose of 0.7–1.2 mg/kg twice daily for 28 days resulted in elevations of BUN and CREA (n = 4), as well as alanine aminotransferase (n = 3) [17]. Another study on oclacitinib intoxication reported that doses of 10–15 mg/kg can cause acute kidney injury in dogs and cats [26]. Nevertheless, considering the elevation of AST, GGT and CREA observed in this study, evaluating baseline renal and hepatic function is recommended before prescribing oclacitinib. The CK level exhibited individual variability in the present study. In a previous case study on a dog, long‐term oclacitinib administration may be associated with mild exercise‐induced rhabdomyolysis. In this case, the dog displayed no clinical signs of myopathy, yet developed myoglobinuria following strenuous exercise [27]. To the best of our knowledge, the relationship between oclacitinib and exercise‐induced rhabdomyolysis remains unclear. Consequently, caution should be used in providing long‐term oclacitinib prescription for sport horses or horses with muscle injuries. In a previous long‐term study, twice‐daily oclacitinib administration was well tolerated in dogs. However, several potential adverse effects (e.g., mild and self‐limiting gastrointestinal disturbances, development of mass or carcinoma and other dermatological conditions) were observed [28]. In our study, although changes in biochemical parameters were observed, no adverse effects were detected in 21 days of drug administration. Currently, data regarding the long‐term administration of oclacitinib in horses remain limited. Therefore, caution should be applied when prescribing oclacitinib, along with periodic monitoring of haematological and biochemical parameters. This study had a few limitations. First, the clinical scoring systems for skin lesions and pruritus were evaluated by nonspecialists and not by referral clinicians, potentially causing variability and inaccuracy. Second, oclacitinib was administered by the owners using different methods (e.g., given whole by hand, placed in the feed tray or ground and mixed in feed/water), which could result in horses not receiving the calculated dosage. Third, there were differences in the types of allergic dermatitis among the horses, as well as the stable locations, weather conditions and opportunities for allergen or insect exposure. Consequently, the improvement of pruritus and skin lesions may have been influenced by these factors. Future studies should sample horses with the same PVAS baseline, explore various therapeutic doses and incorporate a placebo control group. This study supports the efficacy of oclacitinib in reducing pruritus and improving skin lesions in horses with allergic dermatitis. However, significant changes in blood parameters related to renal function, hepatic function and muscle enzyme were seen, although these remained within normal range. Nevertheless, further investigation on the long‐term efficacy and adverse effects of oclacitinib in horses with allergic dermatitis is highly recommended. Future experimental designs should focus on controlling the environment, season, method of drug administration and the inspectors to reduce variability. Conclusions Oclacitinib was an effective alternative treatment for reducing pruritus in the 16 horses with allergic dermatitis treated off‐licence in this study. Cautious administration is recommended in horses with pre‐existing hepatic, renal or muscular disorders. Haematological and biochemical profiles should be periodically monitored during oclacitinib treatment. Environmental control is also crucial for improving skin lesions. Further studies are required to determine the optimum dose and evaluate the safety of long‐term use in horses. Author Contributions Maturawan Tunhikorn: conceptualization, methodology, funding acquisition, supervision, project administration, formal analysis. Photchanun Maneephan: writing – original draft, formal analysis, data curation, investigation. Natcha Tovanakasame: data curation, formal analysis, investigation, writing – original draft. Chalidaporn Kampang: data curation, formal analysis, investigation, writing – original draft. Pusprapa Jandee: conceptualization, methodology. Panpanga Sangsuriya: formal analysis, validation, methodology. Nuttawut Nuchprayoon: writing – review and editing, data curation, investigation. Funding The drug used in this study was sponsored by Zoetis (Thailand) company limited. Research fund was subsidised by the Faculty of Veterinary Science, Mahidol University. Disclosure The authors did not use the generative AI and AI‐assisted technologies in the manuscript preparation process. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Figure S1: Pruritus Visual Analog Scale (PVAS; range 0–10) scores adapted from Cosgrove et al. [11]. Figure S2: Veterinarian lesion score (VLS) adapted from Olsen et al. [12] and Miller et al. [13] and Veterinarian alopecia score (VAS) described by Miller et al. [13]. Table S1: Individual haematologic and biochemical parameters before oclacitinib treatment (day 0). Abnormal values are underlined. Table S2: Individual haematologic and biochemical parameters after oclacitinib treatment (day 21). Abnormal values are underlined.